Urolithiasis bei der Langzeitherapie mit GnRH-Agonisten bei Paraphilien – 3 Fallberichte

Zusammenfassung

Unter der forensischen Nachsorge-Behandlung von Sexualstraftätern mit einer Paraphilie traten in der Berliner Nachsorgeambulanz in den letzten 5 Jahren bei 3 von 32 mit GnRH-Analoga medizierten Patienten eine behandlungsbedürftige Urolithiasis auf, wobei zuvor alle 3 Patienten unter der Therapie bereits eine Osteopenie/Osteoporose entwickelt hatten. Dieser Artikel beschreibt diese 3 Fälle und schlägt eine intensivere Berücksichtigung des möglichen Auftretens von Nierensteinen bei antiandrogen behandelten Sexualstraftätern vor.

Abstract

The outpatient forensic aftercare department of the Charité Berlin treated 32 paraphilic sex offenders with GnRH analogues within the past 5 years. Out of those patients, three men suffered from urolithiasis and were in need of treatment. All 3 patients had previously developed osteopenia/osteoporosis while on antiandrogen treatment.

This article describes these 3 cases and suggests an intense consideration of the possible occurrence of urolithiasis in sex offenders on antiandrogen treatment.

Schlüsselwörter

Urolithiasis - GnRH-Agonisten - Paraphilien - Forensische Nachsorge

Key words

urolithiasis - GnRH agonists - paraphilia - forensic aftercare

• Literatur

• 1 Lee JY, Cho KS. Chemical castration for sexual offenders: physicians’ views. J Korean Med Sci 2013; 28: 171-172
• 2 Turner D, Basdekis-Jozsa R, Briken P. Prescription of testosterone-lowering medications for sex offender treatment in German forensic-psychiatric institutions. J Sex Med 2013; 10: 570-578
• 3 Voß T, Klemke K, Schneider-Njepel V et al. Wenn ja, wie lange? – Zur Dauer antiandrogener Behandlung von Sexualstraftätern mit paraphilen Störungen. Eingereicht zur Veröffentlichung FPPK 2015
• 4 Thibaut F. Pharmacological treatment of paraphilias. Isr J Psychiatry Relat Sci 2012; 49: 297-305
• 5 Lösel F, Schmucker M. The effectiveness of treatment for sexual offenders: a comprehensive meta-analysis. J Exp Criminol 2005; 1: 117-146
• 6 Lieske JC, Peña de la Vega LS, Slezak JM et al. Renal stone epidemiology in Rochster, Minnesota: an update. Kidney Int 2006; 69: 760-764
• 7 Long LO, Park S. Update on nephrolithiasis management. Minerva urol Nefrol 2007; 59: 317-325
• 8 Stamatelou KK, Francis ME, Jones CA et al. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 2003; 63: 1817-1823
• 9 Herold G. Herold Innere Medizin 2013; 2013: 653-656
• 10 Türk C, Knoll T, Petrik A. EAU guidelines on urolithiasis. 2014 www.uroweb.org
• 11 Jocham D, Miller K, Bares R et al. 2007 Praxis der Urologie Band I.
• 12 Fisang C, Anding R, Müller SC et al. Urolithiasis – interdisziplinäre Herausforderung in Diagnostik, Therapie und Metaphylaxe. Dtsch Arztebl 2015; 112: 83-91
• 13 Coe FL, Parks JH, Asplin JR et al. The pathogenesis and treatment of kidney stones. N. Engl J Med 1992; 327: 1141-1152
• 14 Sabbagh R. Bones and stones – The link between opsteoporosis and nephrolithiasis. Osteoporosis Update 2009; 13: 5-7
• 15 Izzedine H, Lescure FX, Bonnet F. HIV medication-based urolithiasis. Clin Kidney J. 2014; 7: 121-126
• 16 Audran M, Legrand E. Hypercalciuria. Joint Bone Spine 2000; 67: 509-515
• 17 Cauley JA, Fullman RL, Stone KL et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 2005; 16: 1525-1537
• 18 Denburg MR, Leonard MB, Haynes K et al. Risk of fracture in urolithiasis: A population-based cohort study using the health improvement network. Clin J Am Soc Nephrol 2014; 9: 2133-2140
• 19 Sakhaee K, Maalouf NM, Kumar R et al. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int 2011; 79: 393-403
• 20 Trinchieri Nespoli R, Ostini F. et al. A study of dietary calcium and other nutrients in idiopathic renal calcium stone formers with low bone mineral content. J Urol 2002; 159: 654-657
• 21 Keller JJ, Lin CC, Kang JH et al. Association between osteoporosis and urinary calculus: evidence from a population-based study. Osteoporos Int 2013; 24: 651-657
• 22 Giltay EJ, Gooren LJ. Potential side effects of androgen deprivation treatment in sex offenders. J Am Acad Psychiatry Law 2009; 37: 53-58
• 23 Moe OW. Kidney stones: Pathophysiology and medical management. Lancet 2006; 367: 333-344
• 24 Mohile SG, Mustian K, Bylow K et al. Management of complications of androgen deprivation therapy in the older man. Oncology/Hepatology 2009; 70: 235-255
• 25 Lee YH, Huang WC, Huang JK et al. Testosteron enhances whereas estrogen inhibits calcium oxalate stone formation in ethylene glycol treated rats. J Urol 1996 Aug 1992; 156 2Pt1 502-505
• 26 Yagisawa T, Ito F, Osaka Y et al. The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol 2001; 166: 1078-1082